Federal Joint Committee/Institute for Quality and Efficiency in Health Care (G-BA/IQWiG; Germany) and the National Institute … approach taken by NICE seems to be more open and less restrictive as compared with G-BA/IQWiG. Any kind of potentially relevant … sensitivity analyses before making a recommendation regarding reimbursement. By contrast, G-BA/IQWiG bases its assessment and …

Federal Joint Committee/Institute for Quality and Efficiency in Health Care (G-BA/IQWiG; Germany) and the National Institute … approach taken by NICE seems to be more open and less restrictive as compared with G-BA/IQWiG. Any kind of potentially relevant … sensitivity analyses before making a recommendation regarding reimbursement. By contrast, G-BA/IQWiG bases its assessment and …

Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …

(FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors … to descriptive statistics, differences between IQWiG and FJC were tested and explored by agreement statistics (Cohen … of the appropriate comparative therapy had a high influence on FJC's appraisals deviating from IQWiG's addenda …

Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …

(FJC) to the HTA body (IQWiG) and their agreement with FJC decisions and to identify potential additional decisive factors … to descriptive statistics, differences between IQWiG and FJC were tested and explored by agreement statistics (Cohen … of the appropriate comparative therapy had a high influence on FJC’s appraisals deviating from IQWiG’s addenda …

Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz … assess the additional benefit of the new drug. However, the Institute for Quality and Efficiency in Health Care (IQWiG …

The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social … unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints …

Background: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of … appraisals of medicines that were withdrawn from the German market since the introduction of AMNOG in 2011. Methods: Medications …-BA (average 'no additional benefit' rating for all AMNOG products: 47%). Of the 22 medicines, 15 (68%) were recommended by at …